New data from teprotumumab phase 3 OPTIC study shows significantly reduced double vision
Horizon Therapeutics announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease compared with placebo, including diplopia, QoL and CAS. October 11, 2019